Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hypromellose + xylitol + sodium hyaluronate is an investigational combination nasal spray being evaluated for the postoperative management of chronic rhinosinusitis (CRS) in patients undergoing functional endoscopic sinus surgery (FESS). The formulation combines three active components: hypromellose (HPMC), a viscosity-enhancing polymer that acts as a mucosal lubricant and protectant; xylitol, a naturally occurring sugar alcohol with known antibiofilm and osmotic properties in the sinonasal cavity; and sodium hyaluronate (hyaluronic acid), a glycosaminoglycan that supports mucosal wound healing and hydration. The combination acts primarily through a physical, mucoprotective mechanism to support mucociliary clearance and mucosal healing without targeting specific biological receptors. It is being evaluated in a randomized, double-blind, within-patient postoperative Phase 2 clinical study.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hypromellose + xylitol + sodium hyaluronate.